Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes

Journal of Cellular Biochemistry

Volumn 66, Issue 1, 1997, Pages 27-36

  Puri, Pier Lorenzo ^a,b   Medaglia, Stefania ^a,b   Cimino, Letizia ^a,b   Maselli, Carlo ^a,b   Germani, Antonia ^c   De Marzio, Elisabetta ^a,b   Levrero, Massimo ^a,b   Balsano, Clara ^a,d  

^a Fondazione A Cesalpino Univ R   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c INSTITUT COCHIN   (France)

^d UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Cell cycle; Doxorubicin adriamicin; E2F; MyoD; p21

Indexed keywords

DOXORUBICIN; PROTEIN P21;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; DNA DAMAGE; DNA DETERMINATION; DNA SYNTHESIS; DRUG EFFECT; GROWTH INHIBITION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ANIMALIA;

EID: 0030741255     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-4644(19970701)66:1<27::aid-jcb4>3.0.co;2-#     Document Type: Article

References (36)

1. Andrés V, Walsh K (1996): Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol 132:657-666.
2. Benezra R, Davis R, Lockston L, Turner DL, Weintraub H (1990): The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61:49-59.
3. Chittenden T, Livingston D, DeCaprio JA (1993): Cell cycle analysis of E2F in primary human T cells reveals novel E2F complexes and biochemically distinct forms of free E2F. Mol Cell Biol 13:3975-3983.
4. Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Condorelli G, Sun Y, Colburn N, Calabretta B, Giordano A (1994): p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 54:5556-5560.
5. Cobrinik D, Whyte P, Peeper D, Jacks T, Weinberg R (1993): Cell cycle specific association of E2F with the p130 E1A-binding protein. Genes Dev 7:2392-2404.
6. Corbeil HB, Whyte P, Branton PE (1995): Characterization of transcription factor E2F complexes during muscle and neuronal differentiation. Oncogene 11:909-920.
7. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, Macdonald S, Pulford KAF, Stein H, Mason DY (1984): Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219-229.
8. Crescenzi M, Fleming TP, Lassar AB, Weintraub H, Aaronson SA (1990): MyoD induces growth arrest independent of differentiation in normal and transformed cells. Proc Natl Acad Sci USA 87:8442-8446.
9. Crescenzi M, Soddu S, Tatò F (1995): Mitotic cell cycle reactivation in terminally differentiated cells by adenovirus infection. J Cell Physiol 162:26-35.
10. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684.
11. Gartenhaus RB, Wang P, Hoffman P (1996): Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with Adriamicin by using a p53-independent pathway. Proc Natl Acad Sci USA 93:265-268.
12. Gu W, Schneider JW, Condorelli G, Kaushal S, Mahdavi V, Nadal-Ginard B (1993): Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 72:309-324.
13. Guo K, Wang J, Andrés V, Smith R, Walsh K (1995). MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol 15:3823-3829.
14. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar A (1995): Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21. Science 267:1018-1021.
15. Ko LJ, Prives C (1996): P53: Puzzle and paradigm. Genes Dev 10:1054-1072.
16. Kurabayashi M, Jeyaseelan R, Kedes L (1993): Antineoplastic agent doxorubicin inhibits myogenic differentiation of C2 myoblasts. J Biol Chem 268:5524-5528.
17. Kurabayashi M, Jeyaseelan R, Kedes L (1994): Doxorubicin represses the function of the myogenic Helix-Loop-Helix transcription factor MyoD. J Biol Chem 269:6031-6039.
18. Lassar A, Munsterberg A (1994): Wiring diagrams: Regulatory circuits and the control of skeletal myogenesis. Curr Biol 6:432-442.
19. La Thangue NB (1996): E2F and the molecular mechanism of early cell-cycle control. Biochem Soc Trans 24:54-59.
20. Lees, E Faha B, Dulic V, Reed S, Harlow E (1992): CyclinE/ cdk2 and cyclinA/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev. 6:2705-2713.
21. MacLachlan TK, Sang N, Giordano A (1995): Cyclins, cyclin-dependent kinases and Cdk inhibitors: Implication in cell cycle control and cancer. Crit Rev Eukariotic Gene Exp 5:127-156.
22. Nadal-Ginard B (1978): Commitment, fusion and biochemical differentiation of a myogenic cell line in the absence of DNAsynthesis. Cell 15:855-864.
23. Natoli G, Avantaggiati ML, Chirillo P, Pun PL, Ianni A, Balsano C, Levrero M (1994): Ras-and Raf-dependent activation of cJun transcriptional activity by the hepatitis B virus transactivator pX. Oncogene 9:2837-2843.
24. Olson EN, Klein WH (1994): bHLH factors in muscle development: Dead lines and commitments, what to leave in and what to leave out. Genes Dev. 8:1-8.
25. Pagano M, Draetta G, Jansen-Durr P (1992): Association of cdk2 kinase with the transcription factor E2F during S phase. Science 255:1144-1147.
26. Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M (1995): Reative oxygen intermediates mediate angiotensinII-induced cJun/cFos heterodimer DNA binding activity and proliferative/hypertrophic responses in myogenic cells. J Biol Chem 270:22129-22134.
27. Puri PL, Avantaggiati ML, Balsano C, Sang N, Graessmann A, Giordano A, Levrero M (1997a): P300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription. EMBO J 16:369-383.
28. Pun PL, Balsano C, Burgio VL, Chirillo P, Natoli G, Ricci L, Mattei E, Graessmann A, Levrero M (1997b): MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes. Oncogene 14: 1171-1184.
29. Shin EK, Shin A, Paulding C, Schaffausen B, Yee AS (1995): Multiple changes in E2F function and regulation occur upon muscle differentiation. Mol Cell Biol 15:2252-2262.
30. Shiyanov P, Bagchi S, Adami G, Kokontis J, Hay N, Arroyo M, Morozov A, Rachaudhury P (1996): p21 disrupts the interaction between cdk2 and the E2F-p130 complex. Mol Cell Biol 16:737-744.
31. Sorrentino V, Pepperkok R, Davis RL, Ansorge W, Philipson L (1990): Cell proliferation inhibited by MyoD independently of differentiation. Nature 345:813-815.
32. Stockdale FE, Holtzer H (1961): DNA synthesis and myogenesis. Exp Cell Res 24:508-520.
33. Tommasi S, Pfeiffer GP (1995): In vivo structure of the human cdc2 promoter: Release of a p130-E2F4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression. Mol Cell Biol 15:6901-6913.
34. Waldmann T, Lengauer C, Kinzler KW, Vogelstein B (1996): Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (London) 381:713-716.
35. Yaffe D, Saxel O (1977): Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle Nature (London) 270:225-227.
36. Zhang H, Xiong Y, Beach D (1994): p21-containing cyclin kinases exists in both active and inactive states. Genes Dev 8:1750-1758.